Shanghai, China, January 24 – The “Report on the Media Coverage and Influence of the 7th China International Import Expo” (hereinafter referred to as the “Report”) has been officially released. Compiled jointly by the China International Import Expo Bureau and the Beijing People Online Network, the “Report” comprehensively, multidimensionally, and scientifically presents the communication impact of this year’s Import Expo through rich data and visuals. Asieris has been selected as the “Top 10 Exhibitors with Communication Influence” in the Innovation Incubation Special Section of the 7th CIIE.
At this year’s Import Expo, the Innovation Incubation Special Section has been upgraded to showcase 360 innovative items from 34 countries and regions, including Asieris among them. These exhibits represent the development direction of new quality productive forces and aim to provide support for enterprise advancement, achieving a dual enhancement in scale and quality.
In collaboration with key partners, the company is showcasing a pioneering prevention and control system aimed at accelerating the elimination of cervical cancer in the CIIE Innovation Incubation Special Section. This includes a range of cutting-edge innovative products and technologies. Asieris has debuted the innovative product APL-1702, the “world’s first and China’s premiere” non-invasive treatment for precancerous cervical lesions. It is poised to revolutionize the traditional surgical treatment landscape, speeding up the eradication of cervical cancer while also preserving female fertility. This innovation aids China in pioneering a fertility-friendly approach to cervical cancer prevention and control.
CIIE is an excellent window through which China upholds its commitment to openness to the outside world. Asieris will further enhance its communication influence, collaborate with colleagues from all walks of life, and bring more innovative products to patients in China and around the world.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.